CVS vs PFE
CVS Health · Pfizer
| CVS CVS Health Healthcare | PFE Pfizer Healthcare | |
|---|---|---|
| Market | ||
| Price | $90.25 -0.09% | $30.52 +1.90% |
| Market cap | $115.4B | $174.0B |
| P/E (TTM) | 23.6 | 40.1 |
| Dividend yield | 3.49% | 5.38% |
| 52-week range | $69.51 – $110.68 | $23.62 – $30.67 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | CVS Health's Aetna MBR Just Hit 84.6% — Five Straight Beats Say The Turnaround Is Real (C… Jun 30, 2026 | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 |
| Latest earnings | ||
| Reported | Aug 5, 2026 | — |
| Revenue | $106.1 billion +7.3% YoY | — |
| EPS | $2.31 | — |
| Guidance | Guidance raised | — |
| Revenue growth, last 4 reports | +7.3% | — |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page | |
Shared topics: GLP-1
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.